8 reports of this reaction
3.4% of all NYSTATIN AND TRIAMCINOLONE ACETONIDE reports
#4 most reported adverse reaction
PRURITUS is the #4 most commonly reported adverse reaction for NYSTATIN AND TRIAMCINOLONE ACETONIDE, manufactured by Alembic Pharmaceuticals Inc.. There are 8 FDA adverse event reports linking NYSTATIN AND TRIAMCINOLONE ACETONIDE to PRURITUS. This represents approximately 3.4% of all 237 adverse event reports for this drug.
Patients taking NYSTATIN AND TRIAMCINOLONE ACETONIDE who experience pruritus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRURITUS is moderately reported among NYSTATIN AND TRIAMCINOLONE ACETONIDE users, representing a notable but not dominant share of adverse events.
In addition to pruritus, the following adverse reactions have been reported for NYSTATIN AND TRIAMCINOLONE ACETONIDE:
The following drugs have also been linked to pruritus in FDA adverse event reports:
PRURITUS has been reported as an adverse event in 8 FDA reports for NYSTATIN AND TRIAMCINOLONE ACETONIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRURITUS accounts for approximately 3.4% of all adverse event reports for NYSTATIN AND TRIAMCINOLONE ACETONIDE, making it a notable side effect.
If you experience pruritus while taking NYSTATIN AND TRIAMCINOLONE ACETONIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.